• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Will Baxter renew Medgenics drug pump deal?

October 14, 2011 By drugdelivery

Baxter
Medgenics

Medgenics Inc. (NYSE:MDGN) said it’s in talks with Baxter International (NYSE:BAX) over their deal to co-develop a drug-delivery pump using, but Baxter itself is mum on the topic.

San Francisco and Misgav, Israel-based Medgenics is developing a "sustained-action therapeutic protein delivery technology" for chronic diseases it calls the Biopump, according to its website. The technology "is made from the patient’s own skin and is implanted in a simple procedure to work inside the patient’s body, to produce and deliver the active protein steadily over a sustained period," according to the site.

Today Medgenics said its deal with Baxter, to co-develop the Factor VIII Biopump, expired Sept. 30.

Sign up to get our free newsletters delivered right to your inbox

"The company confirms that it is in active discussions with Baxter regarding the terms for possible further collaboration," according to a press release.

Baxter did not immediately respond to a request for comment, according to Reuters.

The $7 million pact, inked in 2009, called for the duo to develop the pump to treat hemophilia.

"Biopump does not have the drawbacks of gene therapy, nor is it based on techniques that can only be performed by two people in the world or require technology as specialized as a NASA space capsule," CEO Andrew Pearlman told parterningNEWS at the time.

"This is being developed to be a practical, automated process that will be highly reliable and cost effective. We believe it can be performed at any medical center, even at local centers, and perhaps even by trained nurse practitioners."

Filed Under: Drug-Device Combinations Tagged With: Baxter International, Medgenics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS